{"title":"The mechanism and related research progress of GLP-1 receptor agonists in treating Alzheimer's disease.","authors":"Xiao-Cheng Zhu, Yi-Wen Wang, Hong-Wen Zhou","doi":"10.16288/j.yczz.24-178","DOIUrl":null,"url":null,"abstract":"<p><p>GLP-1 receptor agonists are primarily used clinically for the treatment of type 2 diabetes and have the potential for weight loss, while they are currently expanding their horizons in the treatment of hypertension, non-alcoholic liver disease, depression, and neurodegenerative diseases. In particular, in the treatment of Alzheimer's disease, a large number of animal models and a handful of clinical studies have demonstrated the potential efficacy of GLP-1 receptor agonists, making it highly probable that they will become a new entrant in the drug list for Alzheimer's disease. At present, the research on the mechanism of GLP-1 receptor agonist in the treatment of Alzheimer's disease is mainly based on in-depth analysis of the pathogenesis of Alzheimer's disease and exploration of the mechanism of its comorbidity with diabetes. This article mainly reviews the latest advances in the mechanism of GLP-1 receptor agonists in the treatment of Alzheimer's disease, introduces the latest achievements in animal studies and clinical studies, and aims to provide reference for the subsequent relevant basic research and clinical application.</p>","PeriodicalId":35536,"journal":{"name":"遗传","volume":"46 12","pages":"1017-1027"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"遗传","FirstCategoryId":"1091","ListUrlMain":"https://doi.org/10.16288/j.yczz.24-178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
GLP-1 receptor agonists are primarily used clinically for the treatment of type 2 diabetes and have the potential for weight loss, while they are currently expanding their horizons in the treatment of hypertension, non-alcoholic liver disease, depression, and neurodegenerative diseases. In particular, in the treatment of Alzheimer's disease, a large number of animal models and a handful of clinical studies have demonstrated the potential efficacy of GLP-1 receptor agonists, making it highly probable that they will become a new entrant in the drug list for Alzheimer's disease. At present, the research on the mechanism of GLP-1 receptor agonist in the treatment of Alzheimer's disease is mainly based on in-depth analysis of the pathogenesis of Alzheimer's disease and exploration of the mechanism of its comorbidity with diabetes. This article mainly reviews the latest advances in the mechanism of GLP-1 receptor agonists in the treatment of Alzheimer's disease, introduces the latest achievements in animal studies and clinical studies, and aims to provide reference for the subsequent relevant basic research and clinical application.
期刊介绍:
Hereditas is a national academic journal sponsored by the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences and the Chinese Society of Genetics and published by Science Press. It is a Chinese core journal and a Chinese high-quality scientific journal. The journal mainly publishes innovative research papers in the fields of genetics, genomics, cell biology, developmental biology, biological evolution, genetic engineering and biotechnology; new technologies and new methods; monographs and reviews on hot issues in the discipline; academic debates and discussions; experience in genetics teaching; introductions to famous geneticists at home and abroad; genetic counseling; information on academic conferences at home and abroad, etc. Main columns: review, frontier focus, research report, technology and method, resources and platform, experimental operation guide, genetic resources, genetics teaching, scientific news, etc.